20
views
0
recommends
+1 Recommend
5 collections
    0
    shares

      Call for Papers: Extracellular Vesicles: Broadening Horizons in Neurodegenerative Diseases

      Submit here by September 30, 2025

      About Neurodegenerative Diseases: 1.9 Impact Factor I 5.9 CiteScore I 0.648 Scimago Journal & Country Rank (SJR)

      Call for Papers: Epidemiology of CKD and its Complications

      Submit here by August 31, 2024

      About Kidney and Blood Pressure Research: 2.3 Impact Factor I 4.8 CiteScore I 0.674 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Impact of COVID-19 on Patient Behavior to Stroke Symptoms in China

      letter

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dear Editor, The COVID-19 outbreak has had a major impact across the whole of China, affecting all aspects of people's daily lives and triggered psychological problems of anxiety and panic [1]. During the peak period of the outbreak in February and March 2020, the implementation of national policies to avoid social gatherings and travel to high-risk areas [2] resulted in hospitals reducing outpatient clinics and many services were restricted to urgent cases. Consequently, clinical research abruptly ceased, hospitals suspended ethics committee submissions and their review, and few in-person participant assessments were conducted. China is now emerging from this difficult period, but the shadow of COVID-19 continues, as we have encountered during initiation of the INTEnsive ambulance-delivered blood pressure Reduction in hyper-ACute stroke Trial (INTERACT4) (ClinicalTrials.gov NCT03790800, and Chinese Trial Registry ChiCTR1900020534). As the effectiveness of reperfusion therapy in highly time-dependent, public health strategies encourage patients to urgently call an ambulance, so that they can present rapidly to hospital after the onset of symptoms suggestive of acute stroke, most popularly defined by the Face symmetry, Arm weakness, Speech slurring, and Time to call (FAST) tool. We wish to highlight how COVID-19 has jeopardized this approach by adversely influencing the behavior of patients with suspected stroke. INTERACT4 is a multicenter, prospective, randomized, open, blinded outcome assessed, trial of prehospital, ambulance-administered, intensive blood pressure-lowering treatment in patients with FAST-positive presumed acute stroke within 2 h from last known well. We launched the study on March 8, 2020, and the first patient was enrolled 2 weeks later. Until May 7, 2020, 12 patients have met the eligibility criteria from 84 patients screened across 4 hospitals in expanding research networks in Shanghai and Chengdu. This screened eligibility rate (14% [8/59]) in the Emergency Department of the project lead hospital in Shanghai is much lower than that recorded (32% [8/25]) in the period before the pandemic (20 April to July 1, 2017). The main reason that patients were excluded according to the ambulance screening logs is “delayed time from symptom onset” (>2 h [n = 39]). The percentage of exceeding the time window among excluded patients during the pandemic (59% [30/51]) is higher than that recorded in a similar period before the pandemic (41% [7/17]) at the lead hospital. These patients (or their family members) indicated that they postponed calling the emergency hotline due to concerns of “getting infected” from being exposed at a “high-risk” hospital, and their first reaction was to wait and hope that the symptom(s) would mitigate or disappear. Moreover, parallel screening logs at participating hospitals indicate that many patients with mild stroke-related deficits chose to travel to hospital in their own vehicle, again to reduce a perceived high risk of infection via the ambulance. Although “time is brain” is critical for effective reperfusion therapy, COVID-19 has clearly impacted the behavior of patients in China, as inferred elsewhere [3], with the likelihood that this will have flow-on adverse effects in reducing the potential for recovery from stroke and increasing the impact of subsequent disability on families and society. Although various clinical guidelines for the management of stroke during the COVID-19 pandemic have been released [4], additional efforts are needed to reassure the population and encourage people to seek rapid access to stroke services in order to receive essential interventions. Conflict of Interest Statement C.S.A. holds a Senior Investigator Fellowship of the National Health and Medical Research Council of Australia and reports honoraria and travel reimbursement and grants from Takeda, China. The other authors have no conflicts of interest to declare. Funding Sources No funding sources to report for the manuscript. Author Contributions C.S.A. and L.S. contributed to the concept and rationale for the study. M.O. and L.S. wrote the first draft of the manuscript with inputs from C.S.A. All authors commented upon and approved the final version of the manuscript for publication.

          Related collections

          Most cited references3

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          A nationwide survey of psychological distress among Chinese people in the COVID-19 epidemic: implications and policy recommendations

          The Coronavirus Disease 2019 (COVID-19) epidemic emerged in Wuhan, China, spread nationwide and then onto half a dozen other countries between December 2019 and early 2020. The implementation of unprecedented strict quarantine measures in China has kept a large number of people in isolation and affected many aspects of people’s lives. It has also triggered a wide variety of psychological problems, such as panic disorder, anxiety and depression. This study is the first nationwide large-scale survey of psychological distress in the general population of China during the COVID-19 epidemic.
            • Record: found
            • Abstract: found
            • Article: not found

            Collateral Effect of Covid-19 on Stroke Evaluation in the United States

            To the Editor: The effect of the Covid-19 pandemic on medical care for conditions other than Covid-19 has been difficult to quantify. 1 Any decrease in care for patients with acute conditions such as ischemic stroke may be consequential because timely treatment may decrease the incidence of disability. 2-4 We used the numbers of patients in a commercial neuroimaging database associated with the RAPID software platform (iSchemaView) as a surrogate for the quantity of care that hospitals provided to patients with acute ischemic stroke. This software system is typically used to select patients who may benefit from endovascular thrombectomy by identifying occlusions of major brain arteries or regions of the brain with potentially reversible ischemia that have not become infarcted. 5 Imaging data with demographic information are uploaded in real time to a data repository. The vendor of RAPID was not involved in the analysis or interpretation of the data or the writing of this letter. The first author serves on the medical advisory board of the vendor, and the last author is a consultant to the vendor. No confidentiality agreements related to this analysis are in place between the authors and this company. We had access to data on 231,753 patients who underwent imaging processed with RAPID software in 856 hospitals in the United States from July 1, 2019 through April 27, 2020. The daily counts of unique patients who underwent imaging decreased in March 2020 (Figure 1). We therefore chose to compare the mean daily counts per hospital of patients in the RAPID system in an ostensibly prepandemic 29-day epoch from February 1, 2020, through February 29, 2020, with the mean daily counts per hospital of patients in a 14-day epoch during the early pandemic, from March 26, 2020, through April 8, 2020. During the prepandemic epoch, the numbers of patients per hospital who underwent imaging were similar to the baseline numbers immediately before the prepandemic epoch. The nadir of the daily counts after the first case of Covid-19 was reported in the United States occurred during the 14-day epoch. The number of patients who underwent imaging decreased by 39%, from 1.18 patients per day per hospital in the prepandemic epoch to 0.72 patients per day per hospital in the early-pandemic epoch (see Figs. S1 and S2 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). An apparent increase in the number of patients who underwent imaging after the early-pandemic epoch warrants further investigation. The decrease in the use of stroke imaging from the prepandemic epoch to the early-pandemic epoch was seen across all age, sex, and stroke severity subgroups (Table S1); this suggests a decrease in the number of evaluations both in patients with severe strokes and in nonelderly patients who may have been at low risk for Covid-19 complications. Decreases in the numbers of patients who underwent stroke imaging were seen in most states and across a range of hospital volumes (Fig. S3 and Table S2). These decreases suggest that differences in regional incidences of Covid-19 were not the primary cause of decreased use of stroke imaging. Our analysis has limitations. We used a surrogate for the amount of care provided, and the database, which pertains predominantly to patients who were under consideration for endovascular thrombectomy at designated stroke centers, may not reflect the care provided at other hospitals. We found that the collateral effect of Covid-19 was a decrease of approximately 39% in the numbers of patients who received evaluations for acute stroke between two recent epochs in U.S. hospitals.
              • Record: found
              • Abstract: not found
              • Article: not found

              Novel coronavirus pneumonia prevention guidance for public (in Chinese)

              (2020)

                Author and article information

                Journal
                Cerebrovasc Dis
                Cerebrovasc Dis
                CED
                Cerebrovascular Diseases (Basel, Switzerland)
                S. Karger AG (Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH-4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.com )
                1015-9770
                1421-9786
                8 October 2020
                : 49
                : 5
                : 570-571
                Affiliations
                [1] aThe George Institute for Global Health at Peking University Health Science Center, Beijing, China
                [2] bThe George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
                [3] cShanghai East Hospital, Tongji University, Shanghai, China
                [4] dNeurology Department, Royal Prince Alfred Hospital, Sydney Health Partners, Sydney, New South Wales, Australia
                Author notes
                *Craig S. Anderson, The George Institute for Global Health, Level 10, King George V Building, PO Box M201, Missenden Road, Sydney, NSW 2050 (Australia), canderson@ 123456georgeinstitute.org.au
                Article
                ced-0049-0570
                10.1159/000511394
                7649680
                33032275
                65a30fbc-62da-4e08-890b-0996a164baeb
                Copyright © 2020 by S. Karger AG, Basel

                This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                : 2 June 2020
                : 6 September 2020
                : 2020
                Page count
                References: 4, Pages: 2
                Categories
                Letter to the Editor

                Neurology
                covid-19,stroke,patient behavior,coronavirus
                Neurology
                covid-19, stroke, patient behavior, coronavirus

                Comments

                Comment on this article

                Related Documents Log